Last reviewed · How we verify
Augmentin (ES)-600
Augmentin ES-600 is a combination antibiotic that inhibits bacterial cell wall synthesis by blocking penicillin-binding proteins, with enhanced coverage against beta-lactamase-producing organisms.
Augmentin ES-600 is a combination antibiotic that inhibits bacterial cell wall synthesis by blocking penicillin-binding proteins, with enhanced coverage against beta-lactamase-producing organisms. Used for Acute otitis media in pediatric patients, Sinusitis, Community-acquired pneumonia.
At a glance
| Generic name | Augmentin (ES)-600 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Augmentin ES-600 contains amoxicillin and clavulanic acid. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall formation by inhibiting penicillin-binding proteins. Clavulanic acid is a beta-lactamase inhibitor that protects amoxicillin from degradation by bacterial beta-lactamases, extending the spectrum of activity to include beta-lactamase-producing strains that would otherwise be resistant to amoxicillin alone.
Approved indications
- Acute otitis media in pediatric patients
- Sinusitis
- Community-acquired pneumonia
- Urinary tract infections
- Skin and soft tissue infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reaction
Key clinical trials
- A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS (PHASE2)
- Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India (PHASE4)
- Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Augmentin (ES)-600 CI brief — competitive landscape report
- Augmentin (ES)-600 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI